Results 211 to 220 of about 112,050 (329)

Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type‐B inhibitor: A Cross‐Sectional, Cohort Study [PDF]

, 2015
Khashayar Dashtipour, Jack J. Chen, Camellia Kani, Khaled Bahjri, Mark Ghamsary   +4 more
openalex   +1 more source

Evaluating the inhibitory efficacy of Oxalis phytocompounds on monoamine oxidase B: An integrated approach targeting age related neurodegenerative diseases through molecular docking and dynamics simulations. [PDF]

PLoS One
Shrestha RLS, M C S, Tamang A, Poudel M, Parajuli N, Shrestha A, Shrestha T, Bharati S, Maharjan B, Marasini BP, Adhikari Subin J.   +10 more
europepmc   +1 more source

Platelet Serotonin (5-HT) Concentration, Platelet Monoamine Oxidase B (MAO-B) Activity and HTR2A, HTR2C, and MAOB Gene Polymorphisms in Asthma. [PDF]

Biomolecules, 2023
Konjevod M, Sreter KB, Popovic-Grle S, Lampalo M, Tudor L, Jukic I, Nedic Erjavec G, Bingulac-Popovic J, Safic Stanic H, Nikolac Perkovic M, Markeljevic J, Samarzija M, Pivac N, Svob Strac D.   +13 more
europepmc   +1 more source

Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques

, 2015
Rafael J. Rojas, Dale E. Edmondson, Terri Almos, Roderick H. Scott, Mark E. Massari   +4 more
openalex   +1 more source

Conformation Study and Design of Novel 6-Hydroxybenzothiazole-2- Carboxamides as Potentially Potent and Selective Monoamine Oxidase B Inhibitors for Neuroprotection. [PDF]

Curr Top Med Chem
Xie D, Guo P, Zhao Q, Gao Y, Zhang J, Zhou J.   +5 more
europepmc   +1 more source

Two weeks dose range-finding and four weeks repeated dose oral toxicity study of a novel reversible monoamine oxidase B inhibitor KDS2010 in cynomolgus monkeys. [PDF]

Toxicol Res, 2023
Kim KT, Cho DW, Cho JW, Im WJ, Kim DH, Park JH, Park KD, Yang YS, Han SC.   +8 more
europepmc   +1 more source

New class of thio/semicarbazide-based benzyloxy derivatives as selective class of monoamine oxidase-B inhibitors. [PDF]

Sci Rep
Chandran N, Lee J, Prabhakaran P, Kumar S, Sudevan ST, Parambi DGT, Alsahli TG, Pant M, Kim H, Mathew B.   +9 more
europepmc   +1 more source

Examination of betahistine bioavailability in combination with the monoamine oxidase B inhibitor, selegiline, in humans-a non-randomized, single-sequence, two-period titration, open label single-center phase 1 study (PK-BeST). [PDF]

Front Neurol, 2023
Strupp M, Churchill GC, Naumann I, Mansmann U, Al Tawil A, Golentsova A, Goldschagg N.   +6 more
europepmc   +1 more source

Dual Targeting Ligands-Histamine H₃ Receptor Ligands with Monoamine Oxidase B Inhibitory Activity-In Vitro and In Vivo Evaluation. [PDF]

Pharmaceutics, 2022
Łażewska D, Siwek A, Olejarz-Maciej A, Doroz-Płonka A, Wiktorowska-Owczarek A, Jóźwiak-Bębenista M, Reiner-Link D, Frank A, Sromek-Trzaskowska W, Honkisz-Orzechowska E, Królicka E, Stark H, Wieczorek M, Wagner W, Kieć-Kononowicz K, Stasiak A.   +15 more
europepmc   +1 more source

Genetic effect of monoamine oxidase B (MAOB) gene on ASD associated behavior phenotypes [PDF]

, 2017
Deepak Verma, Barnali Chakraborti, Arijit Karmakar, Anindyatama Nandi, Debarshi Paul, Aritrika Sanyal, Johnson Thyparambil, Swagata Sinha, Kochupurackal P. Mohanakumar, Kanchan Mukhopadhyay, Usha Rajamma   +10 more
openalex   +1 more source